Department of Orthopedics and Trauma Surgery, Medical Center - Albert-Ludwigs-University of Freiburg, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Germany.
Bern University of Applied Sciences - Health, Berne, Switzerland.
Scand J Med Sci Sports. 2018 Jan;28(1):4-15. doi: 10.1111/sms.12898. Epub 2017 May 26.
Chronic painful Achilles tendinopathy (AT) is a common disorder among athletes. Sclerotherapy (ST) and prolotherapy (PT) are two promising options among the numerous other conservative therapies. As their efficacy and potential adverse effects (AE) are still unclear, we systematically searched, analyzed, and synthesized the available literature on ST and PT for treating AT. Electronic databases, Google Scholar and articles' reference lists were searched according to PRISMA guidelines. Eligibility criteria were set up according to the PICOS-scheme including human and animal studies. Three authors independently reviewed the results and evaluated methodological quality (Coleman Methodology Score and Cochrane Risk of Bias Assessment). The initial search yielded 1104 entries. After screening, 18 articles were available for qualitative synthesis, six of which were subjected to meta-analysis. The mean Coleman Score of the 13 human studies was 50. Four RCTs were ranked as having a low risk of selection bias. Three of those reported a statistically significant drop in the visual analog scale (VAS) score, one a significant increase in the VISA-A Score. 12 of 13 human studies reported positive results in achieving pain relief and patient satisfaction, whereas only one study's finding differed. Meta-analysis revealed an unambiguous result in favor of the intervention (weighted mean difference D=-4.67 cm, 95% CI -5.56 to -3.76 cm [P<.001]). Only one serious AE and two minor AEs were reported in the entire literature. This systematic review suggests that ST and PT may be effective treatment options for AT and that they can be considered safe. Long-term studies and RCTs are still needed to support their recommendation.
慢性疼痛性跟腱病(AT)是运动员中常见的疾病。硬化疗法(ST)和增生疗法(PT)是众多保守治疗方法中两种有前途的选择。由于其疗效和潜在的不良反应(AE)尚不清楚,我们系统地搜索、分析和综合了 ST 和 PT 治疗 AT 的现有文献。根据 PRISMA 指南,我们在电子数据库、Google Scholar 和文章的参考文献列表中进行了搜索。根据 PICOS 方案设定了纳入标准,包括人类和动物研究。三名作者独立审查结果并评估方法学质量(Coleman 方法学评分和 Cochrane 偏倚风险评估)。最初的搜索产生了 1104 条记录。经过筛选,有 18 篇文章可用于定性综合分析,其中 6 篇进行了荟萃分析。13 项人类研究的平均 Coleman 评分为 50 分。四项 RCT 被评为选择偏倚风险低。其中三项报道了视觉模拟量表(VAS)评分明显下降,一项报道了 VISA-A 评分显著增加。13 项人类研究中有 12 项报告了在缓解疼痛和患者满意度方面的积极结果,而只有一项研究的结果不同。荟萃分析结果明确支持干预措施(加权均数差 D=-4.67cm,95%CI -5.56 至 -3.76cm [P<.001])。整个文献中仅报告了一例严重不良反应和两例轻微不良反应。这项系统评价表明,ST 和 PT 可能是 AT 的有效治疗选择,并且可以认为是安全的。仍需要长期研究和 RCT 来支持其推荐。